Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Phase 2 Interventional Results available

A Study of CLR325 in Chronic Stable Heart Failure Patients.

NCT02696967
View directory record Official record
Conditions
Chronic Stable Heart Failure
Interventions
CLR325, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fit Physicians: Use of Activity Monitors and Activity Integration Program in First Year Medical Students

NCT02778009
View directory record Official record
Conditions
Motor Activity, Body Weight Changes
Interventions
iDEXA Scan, Wellness Lectures, Exercise intervention, Activity monitor
Radiation · Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 25, 2026, 3:30 PM EDT
Recruiting Not applicable Interventional

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

NCT05805709
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation

NCT03323099
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal
Interventions
N-of-1, Data Tracking
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

NCT01762033
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
ASONEP
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Duarte, California • Fort Myers, Florida • Inverness, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Post Market Study Using the Xoft Axxent System

NCT01017549
View directory record Official record
Conditions
Breast Cancer
Interventions
Electronic brachytherapy (Axxent System)
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
10
States / cities
San Mateo, California • Marietta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

NCT01186978
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Counter Attitudinal Advocacy to Change Drinking Behavior

NCT04042909
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Abuse
Interventions
Counter Attitudinal Advocacy, Personalized Normative Feedback
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 26 Years
Enrollment
591 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

NCT01941316
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions
Carfilzomib, Irinotecan
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

NCT05526248
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide(BAY1841788, Nubeqa), Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Sherman Oaks, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

Human Placental-Derived Stem Cell Transplantation

NCT01586455
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Adrenoleukodystrophy, Niemann-Pick Disease, Metachromatic Leukodystrophy, Wolman Disease, Krabbe's Disease, Gaucher's Disease, Fucosidosis, Batten Disease, Severe Aplastic Anemia, Diamond-Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Interventions
Human Placental Derived Stem Cell
Drug
Lead sponsor
New York Medical College
Other
Eligibility
0 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Valhalla, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional

Binocular Vision Anomalies After Cataract and Refractive Surgery

NCT03592615
View directory record Official record
Conditions
Binocular Vision Disorder, Refractive Errors, Cataract
Interventions
cataract surgery, Corneal refractive surgery
Procedure
Lead sponsor
Salus University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 25, 2026, 3:30 PM EDT
Not listed Not applicable Interventional

Adapting the Tumor Board Model for Mental Illness and Cancer

NCT05837598
View directory record Official record
Conditions
Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
Interventions
Virtual Cancer and Mental Health Tumor Board
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

NCT03609593
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Venetoclax, Rituximab
Drug
Lead sponsor
Nicole Lamanna
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Active, not recruiting Not applicable Interventional

RELAX: Reducing Length of Antibiotics for Children With Ear Infections

NCT05608993
View directory record Official record
Conditions
Acute Otitis Media, Pediatric Infectious Disease, Ear Infection
Interventions
High Intensity Intervention, Low Intensity Intervention
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
2 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Active, not recruiting Phase 2 Interventional

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03579316
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Olaparib, Ceralasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

NCT00665106
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
NOVA63035 "Corticosteroid"
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

NCT03200704
View directory record Official record
Conditions
Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Interventions
IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe
Combination Product
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Agile Development of a Digital Exposure Treatment for Youth With Chronic Musculoskeletal Pain

NCT05079984
View directory record Official record
Conditions
Chronic Pain, Exposure, Adolescent Behavior, Child Behavior
Interventions
Graded exposure treatment (GET)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05972733
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214
Biological
Lead sponsor
HilleVax
Industry
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Rolling Hills Estates, California • Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Virtual Reality to Promote Relaxation Prior to Simulation

NCT06318338
View directory record Official record
Conditions
Cancer
Interventions
Virtual Reality Program
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Not applicable Interventional

Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA)

NCT04862689
View directory record Official record
Conditions
Coronary Stenosis
Interventions
Ringer Perfusion Balloon Catheter
Device
Lead sponsor
Vascular Solutions LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Torrance, California • Boston, Massachusetts • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 25, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Impact of Colchicine and Low-dose Naltrexone on COVID-19

NCT04756128
View directory record Official record
Conditions
Covid19
Interventions
Colchicine 0.6 mg, Naltrexone
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 25, 2026, 3:30 PM EDT